152 related articles for article (PubMed ID: 37153042)
41. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
42. [Return of Individual Genomic Results to Germline Pathogenic Variant Carriers of Hereditary Cancer in Population Based Cohort Study].
Ohneda K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):231-236. PubMed ID: 38494798
[TBL] [Abstract][Full Text] [Related]
43. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
44. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
Duan RR; Sun LX; Zhao HW
Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
[No Abstract] [Full Text] [Related]
45. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO
JMIR Res Protoc; 2017 Sep; 6(9):e184. PubMed ID: 28931501
[TBL] [Abstract][Full Text] [Related]
46. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
47. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
48. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
49. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
51. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Shao D; Cheng S; Guo F; Zhu C; Yuan Y; Hu K; Wang Z; Meng X; Jin X; Xiong Y; Chai X; Li H; Zhang Y; Zhang H; Liu J; Ye M
Cancer Sci; 2020 Feb; 111(2):647-657. PubMed ID: 31742824
[TBL] [Abstract][Full Text] [Related]
53. Detection of BRCA1/2 pathogenic variants in patients with breast and/or ovarian cancer and their families. Analysis of 3,458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme.
Doraczynska-Kowalik A; Michalowska D; Matkowski R; Czykalko E; Blomka D; Semeniuk M; Abrahamowska M; Janus-Szymanska G; Mlynarczykowska P; Szynglarewicz B; Pawlak I; Maciejczyk A; Laczmanska I
Front Genet; 2022; 13():941375. PubMed ID: 36171877
[TBL] [Abstract][Full Text] [Related]
54. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
[TBL] [Abstract][Full Text] [Related]
55. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract][Full Text] [Related]
56. Germline multigene panel testing revealed a
Yoshihama T; Hirasawa A; Sugano K; Yoshida T; Ushiama M; Ueki A; Akahane T; Nanki Y; Sakai K; Makabe T; Yamagami W; Susumu N; Kameyama K; Kosaki K; Aoki D
Int Cancer Conf J; 2021 Jan; 10(1):6-10. PubMed ID: 33489693
[TBL] [Abstract][Full Text] [Related]
57. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
58. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
59. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.
Chapman BV; Liu D; Shen Y; Olamigoke OO; Lakomy DS; Barrera AMG; Stecklein SR; Sawakuchi GO; Bright SJ; Bedrosian I; Litton JK; Smith BD; Woodward WA; Perkins GH; Hoffman KE; Stauder MC; Strom EA; Arun BK; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):437-444. PubMed ID: 34582940
[TBL] [Abstract][Full Text] [Related]
60. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
